[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fungal-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fungal-infection":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,67,103,128,154,180,202,231,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390",false,"NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","ALL","18 Years","90 Years",{"count":20,"type":21},400,"ESTIMATED","30 Days","OBSERVATIONAL","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[26,27,28,29,30,31,32,33,34,35],"Pneumonia","Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[27,37,29,38,32,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","RECRUITING","2026-06-26",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2025-11-13",{"date":62,"type":21},"2031-11-13",{"name":64,"class":65},"Azienda Ospedaliero-Universitaria Careggi","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100555331","phase-2-pharmacogenomics-for-better-treatment-of-fungal-infections-clinical-trial-100555331","NCT06510699","Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial","Randomized Clinical Trial to Evaluate the Use of Genotype-based Dosing of Voriconazole","PRAGMATIC","Inclusion Criteria:\n\n* Age ≥ 2 years.\n* Written informed consent obtained.\n* Decision to prescribe voriconazole.\n* Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible\n\nExclusion Criteria:\n\n* Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA\n* Death is likely imminent within 7 days.\n* Previously randomised to this trial",true,"2 Years",{"count":78,"type":21},104,"INTERVENTIONAL",[81],"PHASE2","This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.",[34,84,85,86],"Haematological Malignancy","Blood Cancer","Infectious Disease",[88,89,90,91,92],"infection","cancer","pharmacogenomic","genotype-based dosing","CYP2C19","2026-04-13",{"date":95,"type":58},"2026-04-16",{"date":97,"type":58},"2025-04-14",{"date":99,"type":21},"2027-03-26",{"name":101,"class":65},"The University of Queensland",7,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":79,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":66},"100627860","phase-1-cd5car-nk-cells-for-refractory-invasive-mold-disease-100627860","NCT07454122","CD5CAR-NK Cells for Refractory Invasive Mold Disease","Off-the-shelf CD5CAR-NK Cells for Refractory Invasive Mold Disease: Phase I Clinical Trial.","CD5CAR-NK","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of probable or proven fungal infection according to EORTC criteria20, who have been treated with the best available antifungal strategy and present at least one of the following criteria indicating inadequate response to antifungal therapy: Increase in fungal infection biomarker levels (serum or bronchoalveolar lavage galactomannan, or serum β-D-glucan) after at least one week of antifungal therapy:\n\n   1. Persistence of positive cultures despite having received ≥2 weeks of appropriate antifungal treatment.\n   2. Radiological worsening of lesions suggestive of fungal infection despite having received ≥2 weeks of appropriate antifungal treatment, and when at least 2 weeks have passed since the previous imaging study.\n   3. Clinical deterioration and microbiological isolation of a fungus resistant to all available antifungal treatments (including cases in which a specific antifungal cannot be administered due to the risk of unacceptable toxicity).\n   4. Rapidly progressive clinical deterioration despite the implementation of all available antifungal measures, conferring a poor prognosis for the patient.\n3. Signing the informed consent form to participate in the clinical trial and to receive CD5CAR-CBNK therapy. If the patient is not in a condition to sign the informed consent form, consent will be requested from the family and patient consent for the study continuation will be obtained as soon as deemed possible.\n\nExclusion Criteria:\n\n1. An expected survival of less than four weeks due to a cause unrelated to the current fungal infection.\n2. Patients with positive HIV serology.\n3. Pregnant or breastfeeding women.\n4. Men or women of childbearing potential unable or unwilling to use highly efficient contraceptive measures from the beginning until the end of the study.","65 Years",{"count":113,"type":21},10,[115],"PHASE1","CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD).\n\nThe study population consists of patients aged ≥18 years with refractory mold infections.\n\nThe number of patients treated will be 10. This is a dose-escalation study including 3 cohorts.",[34],"NOT_YET_RECRUITING","2026-03-02",{"date":121,"type":58},"2026-03-06",{"date":123,"type":21},"2026-05",{"date":125,"type":21},"2029-12",{"name":127,"class":65},"Fundacion Clinic per a la Recerca Biomédica",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":66},"100603968","fungal-vascular-graft-infections-french-multicenter-retrospective-study-100603968","NCT07143409","Fungal Vascular Graft Infections, French Multicenter Retrospective Study","FUNGIVAS","Inclusion Criteria:\n\n* Patients aged ≥ 18 years old with diagnosis of vascular graft and endograft infections (VGEI) in accordance to MAGIC criteria with diagnosis of proven invasive fungal infection according to EORTC criteria.\n* No opposition to re-use data.\n\nExclusion Criteria:\n\n* Patient previously treated for fungal VGEI\n* Patient with suspected VGEI diagnosis based solely on prosthesis implantation in an infected site\n* Poor understanding of French.\n* Patient under legal protection.",{"count":136,"type":21},300,"Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Best therapeutic management is unknown. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France over a 10 year's period in order to describe their epidemiology, clinical features, therapeutic management and outcomes. Focusing on Candida spp. VGEIs, we aim to determine prognosis factors associated with therapeutic management",[34,139],"Vascular Grafting",[141,142,143,144],"vascular graft infection","vascular endograft infection","fungi","Candida","2025-12-09",{"date":147,"type":58},"2025-12-16",{"date":149,"type":21},"2026-01",{"date":151,"type":21},"2027-05",{"name":153,"class":65},"University Hospital, Bordeaux",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":79,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":5},"100349358","ptx3-targeted-antifungal-prophylaxis-100349358","NCT03828773","PTX3-targeted Antifungal Prophylaxis","PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia","PTX3AML","Inclusion Criteria:\n\n1. Signed Informed Consent according to national\u002Flocal regulations.\n2. Age ≥18 years.\n3. Diagnosis of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome in transformation (MDSit) treated with an intensive chemotherapy regimen, including induction \u002F consolidation \u002F salvage remission chemotherapy.\n4. Planned hospital admission for the duration of the neutropenic phase (absolute neutrophils count \\\u003C500 cells\u002Fmm3).\n\nExclusion Criteria:\n\n1. Patients with neutropenia (absolute neutrophils count\\\u003C500 cells\u002Fmm3) upon presentation and prior to chemotherapy initiation.\n2. Patients with a diagnosis of acute promyelocytic leukemia (APL) or AML-M3.\n3. Patients with known history of allergy, hypersensitivity or serious reaction to azole antifungals\n4. Women who are pregnant (positive blood\u002Furine pregnancy test within 10 days before randomization) or breast-feeding.\n5. Diagnosis and treatment for an Invasive Fungal Infection (IFI) within 3 months prior to study enrolment and an Invasive Mold Infection (IMI) at any point prior to or at the time of enrolment.\n6. Severe liver dysfunction, defined as at least one of the following markers: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or alkaline phosphatase above \\>5x upper limit of normality: and\u002For total bilirubin above \\>3x upper limit of normality.\n7. Patients with an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.\n8. Patients who are receiving and cannot discontinue the following drugs at least 24 hours prior to randomization: terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine (because of the possibility of QT prolongation), sirolimus, rifampin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital, mephobarbital), ritonavir, efavirenz, or ergot alkaloids (e.g., ergotamine, dihydroergotamine).\n9. Serious uncontrolled concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol.\n10. Receipt of a prior allogeneic Hematopoietic Cell Transplantation (HCT).\n11. Previous exposure to mold-active prophylaxis (\\>48 hours within 7 days of inclusion).\n12. Patients with relapsed leukemia already included in the trial.\n13. Patient not affiliated to the French social security system\n14. Patient under legal protection (guardianship, curatorship)",{"count":163,"type":21},410,[165],"NA","This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.",[168,34,169,170,171],"Candidiasis","Acute Myeloid Leukemia","Genetic Predisposition","Aspergillosis","2025-12-02",{"date":145,"type":58},{"date":175,"type":58},"2019-02-11",{"date":177,"type":21},"2027-11-30",{"name":179,"class":65},"Bochud Pierre-Yves",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":23,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100599120","isavuconazole-in-critically-ill-patients-efficacy-and-safety-100599120","NCT07080359","Isavuconazole in Critically Ill Patients: Efficacy and Safety","Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety","Inclusion Criteria:\n\n* Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)\n* IFI diagnosis per EORTC\u002FMSGERC 2019 criteria\n\nExclusion Criteria:\n\n* Drug allergy\n* Inherited short QT syndrome\n* Contraindications for nasogastric\u002Foral drug delivery\n* \\\u003C18 years old",{"count":188,"type":21},75,"3 Months","Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.\n\nThis study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:\n\n1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;\n2. Clinical outcomes;\n3. Adverse effects.",[34,171,192],"Mucormycosis","2025-07-14",{"date":195,"type":58},"2025-07-23",{"date":197,"type":21},"2025-08-01",{"date":199,"type":21},"2030-12-31",{"name":201,"class":65},"Shanghai 10th People's Hospital",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":79,"phases":212,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":66},"100340829","phase-4-posaconazole-pharmacokinetics-in-patients-receiving-chemotherapy-or-stem-cell-transplants-100340829","NCT03717623","Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants","Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection","POPULAR","Inclusion Criteria:\n\n* Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Unable to give informed consent.",{"count":211,"type":21},100,[213],"PHASE4","The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.",[216,217,218,219,220,34,221],"Posaconazole","Pharmacokinetics","Invasive Candidiases","Invasive Aspergillosis","Invasive Mycosis","Prophylaxis","2025-02-26",{"date":224,"type":58},"2025-02-28",{"date":226,"type":58},"2019-08-01",{"date":228,"type":21},"2025-12-30",{"name":230,"class":65},"Melbourne Health",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":79,"phases":240,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":261},"100501836","phase-3-efficacy-and-safety-of-high-dose-liposomal-amphotericin-b-for-disseminated-histoplasmosis-in-aids-100501836","NCT05814432","Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS","Efficacy and Safety of High-dose Liposomal Amphotericin B (10 Mg\u002Fkg) for Disseminated Histoplasmosis in AIDS: a Randomized Phase III Trial (INDUCTION Trial)","Inclusion Criteria:\n\n* Adult patients admitted to the centers that will be part of the study\n* Infected by the HIV, regardless of the use of antiretroviral therapy\n* Patients diagnosed with disseminated histoplasmosis, confirmed by classical mycological methods (microscopy, culture or histopathology) or urinary Histoplasma antigen detection\n* Patients with central nervous system (CNS) infection may be included if they have an alternative diagnosis suggestive of another CNS infection\n* Patients using fluconazole for oroesophageal candidiasis may be included\n\nExclusion criteria:\n\n* Refusal to participate in the trial\n* Previous diagnosis of histoplasmosis\n* Pregnant or lactating women\n* Patients with renal failure at any given time (serum creatinine \\> 2x or upper limit of normality (KDIGO, 2012)\n* Previous severe reaction to a polyene antifungal\n* Receipt of more than one dose of a polyene antifungal in the last 48 h\n* Suspected histoplasmosis involving the central nervous system\n* Patients who, in the judgment of the attending physician, have the prospect of death within the next 48 hours after selection, will also be excluded\n* Patients with suspected histoplasmosis involving the central nervous system (CNS), as this condition requires high doses of amphotericin B\n* Patients with the prospect of death in the next 48 hours after selection\n* Patients with a concomitant diagnosis of cryptococcus will be excluded, as will patients with leishmaniasis in treatment or in secondary prophylaxis with amphotericin\n* Patients without the capacity to administer enteral medication-at the discretion of the principal investigator of each center-considering that these patients will not be able to use itraconazole orally or through a feeding tube",{"count":239,"type":21},279,[241],"PHASE3","Phase III trial evaluating the safety and efficacy of a single high dose (10 mg\u002Fkg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg\u002Fkg of liposomal amphotericin B for two weeks) (INDUCTION trial).",[244,245,246,34],"Disseminated Histoplasma Capsulatum Infection","AIDS and Infections","Immunosuppression",[248,249,250,251],"Disseminated Histoplasmosis","AIDS","Liposomal amphotericin B","Fungal infection","2025-01-31",{"date":254,"type":58},"2025-02-04",{"date":256,"type":58},"2025-01-16",{"date":258,"type":21},"2026-11-28",{"name":260,"class":65},"Federal University of Health Science of Porto Alegre",5,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":79,"phases":272,"briefSummary":273,"conditions":274,"keywords":277,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":66},"100560825","phase-4-individualized-first-maintenance-doses-of-voriconazole-through-a-multiparametric-algorithm-100560825","NCT06582186","Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm","Individualization of First Maintenance Doses of Voriconazole Using a Multiparametric Algorithm in Hematology Patients: a Prospective Single-arm Interventional Study","VORIPRECI","Inclusion Criteria:\n\n* adult patient suffering from haematological malignancy\n* followed in the clinical hematology department or in the hematology day hospital of the Grenoble Alps University Hospital\n* consenting to carrying out CYP2C19 genotyping\n* likely to start treatment with voriconazole (for curative or prophylactic purposes as part of care)\n* having signed a written consent to participate\n* affiliated to a social security system\n\nExclusion Criteria:\n\n* comedication with strong inhibitors\u002Finducers (valproic acid, phenytoin, carbamazepine, rifampicin)\n* Subject during exclusion period from another study,\n* Persons referred to in articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant woman, parturient woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons subject to care psychiatric pursuant to articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, persons admitted to a health or social establishment for purposes other than research , minors, person subject to a legal protection measure or unable to express their consent)",{"count":271,"type":21},30,[213],"The goal of this interventional single-arm study is to evaluate the interest of a multiparametric algorithm for individualization of first voriconazole maintenance doses for improvement of initial voriconazole exposure in adult patients with haematological malignancies. The main objective it aims is to determine the percentage of patients with initial voriconazole trough concentrations in the therapeutic range after individualization of first maintenance doses.\n\nParticipants will benefited from individualization of first voriconazole maintenance doses through a previously developed and validated multiparametric algorithm (publication in progress) taking into account CYP2C19 genotype, C reactive protein level and age.",[275,34,276],"Aspergillosis Invasive","Hematologic Malignancy",[278,279,280],"model-informed precision dosing","single-arm prospective interventional study","Simon design","2024-08-29",{"date":283,"type":58},"2024-09-03",{"date":285,"type":21},"2024-10",{"date":287,"type":21},"2027-10",{"name":289,"class":65},"University Hospital, Grenoble"]